The causes of many refractory immunological diseases are not very clear even now. Today, the development of new therapeutic methods is ongoing. In recent years, biologicals, such as anti-TNF alpha antibody agents, are rapidly spreading in this field. Their history in medical therapy, however, is still young. To use them in a more effective and safer manner, we need a wide range of knowledge, sufficient experience, and comprehensive support by a team. Our center treats immunological diseases in various fields at one center in an interdisciplinary manner, so our experience can be shared allowing for much more information to be collected. As a result, a more effective treatment is possible. We are in the global top-class regarding our treatment results for various types of refractory immunological diseases.
Furthermore, we provide leukapheresis, a promising new treatment method, for ulcerative colitis or rheumatoid arthritis patients for whom conventional drug therapies are not effective. In this method, we draw blood out of the body from a vein in the elbow or the thigh on one side of the body, we remove the activated leukocyte cells related to inflammation by filtering the blood, and we return the blood back to the body after purification. No drugs are used, reducing the number of side effects. This therapy method is practiced in Japan. Therefore, medical facilities in Japan have a richer set of experience to call upon than those in Europe and the U.S., Our center, especially, has been proactive in introducing this method.
The School of Medicine, Keio University, our parent facility, was established in 1917, and its first dean was Shibasaburo Kitasato, who is well known to the world for building the foundations of bacteriology and immunology. With this history as our background, we have been continually active in studying immunological diseases.
Although immunological diseases are associated with different disease expressions depending on organs, their pathogenetical mechanisms are common to some extent. Therefore, we can make use of mutual knowledge and therapeutic experience with diseases. On this ground, we have formed a clinical cluster in an interdisciplinary manner, involving the department of rheumatism medicine, the department of gastrointestinal medicine, the department of hematology, the department of orthopedics, the department of dermatology, the department of ophthalmology, the nurse team, and the pharmacist team. We established our center in September 2010 aiming to provide team medical care at the world’s highest level. With the keyword of ”immunity“ as a starting point, experts on various diseases share their accumulated experience. Such an endeavor in immunological medical practice can be said to be a new effort not seen anywhere else in the world.
Furthermore, our center is also active as a base of fundamental clinical studies in relation to refractory immunological diseases. Another purpose of ours is to make contributions to this field by actively developing state-of-the-art therapeutic methods and joint clinical studies among multiple facilities in and outside Japan.
|Treatment Results for Refractory Inflammatory Bowel Disease|
|Cyclosporin (1997−2012)||82 patients|
|Tacrolimus (2009−2012)||65 patients|
|Infliximab (2010−2012)||78 patients|
|Infliximab (2002−2011)||260 patients|
|Adalimumab (2010−2011)||35 patients|
|Efficacy of Various Types of Therapeutic Methods for Ulcerative Colitis (3 Months after Therapy)|
Dr. Toshifumi Hibi
Director of the Center/Professor of the Department of Gastrointestinal Medicine
Refractory immunological diseases are characterized by the fact that it is especially difficult to apply some typical therapies because conditions differ from patient to patient. As the leaders from various fields in Japan get together at our center, the experts share their knowledge and experience, which makes it possible to provide every patient with a preferable, optimal therapy. From the outset, there are thought to be a large number of therapeutic options available for refractory immunological diseases in Japan as opposed to other countries. Even in the context of such excellent service, our center is able to further provide other therapeutic methods including the most advanced trials. Even if you have already heard that therapies are difficult, you should consult with us.
We need, in advance, information on your therapeutic history at your local hospital. You can undergo detailed examinations necessary for the definite diagnosis of ulcerative colitis after you come to Japan.
|External View of Our Hospital||Infusion Room||Hypodermic Injection Guidance Room||View of the New Building of the Immunology Integrated Medical Care Center The new building was completed in 2012 with a floor space of 1,000 m2 and a maximum of 60 beds.|
|Hospital Contact Information|
|Phone (for international visitors) :
+81-3-3353-1211 (Reception, English only)
(Hospital Established 1920)
Gastrointestinal Medicine, Rheumatism Medicine, Hematology, Dermatology, Orthopedics, Ophthalmology
Cash, Debit Card (Hospitalization Payment Only), Credit Card (JCB, DC, VISA, MasterCard, Diners Club, American Express)
35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582
|Approximately 1 minute on foot
from the JR Shinanomachi Station
Approximately 5 minutes on foot
from Toei Subway Kokuritsu-kyogijo Station
Approximately 15 minutes on foot
from Tokyo Metro Yotsuya-sanchome Station
and Toei Subway Aoyama-itchome Station
|60 minutes from Tokyo International Airport
(Haneda Airport) by car
120 minutes from Narita international Airport by car